On the lives of patients and care partners in the US

**WHY did we do this study?**

We wanted to understand how people with IgAN and their care partners (caregivers) describe the impact of IgAN on their lives.

**Impact on the lives of people with IgAN**

**Impact on the lives of care partners**

**HOW did we do this study?**

People with IgAN and their care partners completed an online survey.

The survey asked about the impact of IgAN on their daily lives and emotional well-being.

It asked about their:

- Physical health
- Emotional well-being
- Ability to work
- Most bothersome symptoms

**WHAT were the main results?**

**Impact on people with IgAN**

- Emotional well-being was negatively affected
  - Almost half had depression
  - More than 1 in 4 felt anxious
  - Most felt fear and uncertainty about the future

- Physical health was negatively affected
  - People with IgAN said the most inconvenient symptoms were:
    - About 3 in 4 had lower back pain
    - About 3 in 4 had constipation
    - Nearly 7 in 10 had bone or joint pain

- Daily work was negatively affected
  - Nearly 3 in 4 people with IgAN were employed
  - People missed about 3 hours of work in a 40-hour week
  - While at work, about a quarter of working time was negatively affected

**Impact on care partners**

- Emotional well-being was negatively affected
  - More than 1 in 3 had depression
  - Around 1 in 8 felt anxious
  - Nearly all felt fear and uncertainty about the future

- Daily work was negatively affected
  - More than 9 in 10 care partners were employed
  - People missed about 3 and a half hours of work in a 40-hour week
  - While at work, about a quarter of working time was negatively affected

**WHAT do these results mean?**

IgAN can have negative effects on the daily lives and workplace productivity of people with this disease and the people who care for them.

New treatments may help improve the lives of those affected by IgAN.

This is a summary of a poster originally presented at the European Renal Association Congress in June 2023. For more information, please visit ClinicalTrials.gov NCT05200871.